nivolumab,ipilimumab,pembrolizumab,sunitinib,lenvatinib
eisai,pfizer,merck,bms
['lenva', 'ipi/', 'nivo', 'sunitinib', 'agent', 'rcc,(-irccs),(-srcc),(-urcc)', 'pembro']
lenvatinib and pembro in non-clear cell (n=82) (mainly papillary rcc) looks impressive with rr =53% ( for papillary) . maybe the combinations are better than historical controls for single agent vegf tkis. randomised trials are hard to do, ipi/nivo vs sunitinib awaited #esmo22 
Interested in Urology Cancers, biomarkers and drug development.